June 3rd, 2015

This technology would potentially allow more potent therapeutics to be administered to patients than is currently possible. The reason this is possible is due to the fact that the nanoparticles sequester the drug and allow it to travel throughout the body with minimal toxicity, only releasing the drug directly to the tumor.
A Company spokesman stated: "We are enthusiastic about this potential acquisition. Although Entest has historically focused on veterinary biotechnology, we believe that the acquisition of this nanotechnology would enable us to pursue partnering opportunities in the human market as well as the veterinary market."